ClinicalTrials.gg
CompletedNCT02480881Updated Jul 27, 2017

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

A Phase 1 interventional study of BMS-663068 and Oral Contraceptive in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 2 sites in United States. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-27.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

This is an open-label, single sequence, 4-cycle, 4-treatment, drug-drug interaction (DDI) study in healthy female subjects on oral contraceptives (OC). There is no formal research hypothesis to be statistically tested. It is expected that coadministration of BMS-663068 with OC will not affect the pharmacokinetics (PK) of either ethinyl estradiol (EE) or norethindrone (NE).

02

Conditions studied

  • Infection, Human Immunodeficiency Virus
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 26 is below the median of 113 across 1,304 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy female nonsmoking subjects, ages 18 to 40 years, inclusive with a of 18.0 kg/m2 to 32.0 kg/m2, inclusive
  • Women of child bearing potential with intact ovarian function by medical history and history of regular menstrual cycles must have been on a stable regimen of combination oral containing EE and progestin (28 day regimen) without evidence of breakthrough bleeding or spotting for at least 2 consecutive months prior to Day -1

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness

Other protocol defined exclusion criteria could apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Single Sequence A, B, C, and D

    Treatment A/Cycle 1: OC containing EE and progestin taken by mouth. Treatment B/Cycle 2: OC containing EE and progestin taken by mouth. Treatment C/Cycle 3: Loestrin 1.5/30 taken by mouth. Treatment D/Cycle 4: Loestrin 1.5/30 (alone) and Loestrin 1.5/30 with BMS-663068 taken by mouth.

    Drug: BMS-663068 · Drug: Oral Contraceptive · Drug: Loestrin 1.5/30

Interventions

  • Investigational product

  • DrugOral Contraceptive

    Subject's existing combination OC tablet containing EE and progestin

  • DrugLoestrin 1.5/30

    OC containing EE and norethindrone acetate (NEA)

    Also known as: Junel, Microgestin 1.5/30

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameter Cmax

    Pharmacokinetic parameter includes: maximal observed concentration (Cmax) for EE and NE.

    Time frame: From Day 21 of Treatment C/Cycle 3 to Day 21 of Treatment D/Cycle 4

  2. Pharmacokinetic parameter AUC TAU

    Pharmacokinetic parameter includes: area under the concentration-time curve in one dosing interval (AUC(TAU)) for EE and NE.

    Time frame: From Day 21 of Treatment C/Cycle 3 to Day 21 of Treatment D/Cycle 4

Secondary outcomes

  1. Clinical Safety as Measured by Adverse Event Monitoring.

    Adverse event monitoring

    Time frame: From Day 1 (Treatment A/Cycle 1) to Day 22 (Treament D/Cycle 4)

  2. Clinical Safety as Measured by the Collection of Vital Signs.

    Vital signs assessments

    Time frame: From Day 1 (Treatment A/Cycle 1) to Day 22 (Treament D/Cycle 4)

  3. Clinical Safety as Measured by the Collection of Electrocardiograms (ECGs).

    12-lead ECGs

    Time frame: From Day 1 (Treatment A/Cycle 1) to Day 22 (Treament D/Cycle 4)

  4. Clinical Safety as measured by Physical Examination.

    Physical examinations

    Time frame: From Day 1 (Treatment A/Cycle 1) to Day 22 (Treament D/Cycle 4)

  5. Clinical Safety as Measured by Clinical Laboratory Evaluations.

    clinical chemistry, hematology, and urinalysis.

    Time frame: From Day 1 (Treatment A/Cycle 1) to Day 22 (Treament D/Cycle 4)

  6. Pharmacokinetic Parameter

    Pharmacokinetic parameter: -time of maximum observed concentration (Tmax) for EE and NE.

    Time frame: From Day 21 of Treatment C/Cycle 3 to Day 21 of Treatment D/Cycle 4

07

Study locations

2 sites
  • GSK Investigational Site
    Miami, Florida 33143, United States
  • GSK Investigational Site
    San Antonio, Texas 78209, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Jan 2016, 6 months.

Of 51 industry-sponsored phase 1 interventional studies under Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 13. This study's 6 months is close to that.

Counting every sponsor, half of 78 studies reached it within 10 months; a quarter within 3 and three quarters within 20.

Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2015
First posted
Jun 25, 2015
StartActual
Jul 7, 2015
Primary completionActual
Jan 11, 2016
CompletionActual
Jan 11, 2016
Last update
Jul 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02480881
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 25, 2015
Start date
Jul 7, 2015
Primary completion
Jan 11, 2016
Completion
Jan 11, 2016
Last update
Jul 27, 2017

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fostemsavir

Start the discussion